Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Drug

Sandoz Achieves FDA Milestone with Approval of First US Denosumab Biosimilars

Fineline Cube Mar 6, 2024

The US Food and Drug Administration (FDA) has granted Sandoz (SWX: SDZ), a Switzerland-based pharmaceutical...

Company Drug

Hybio Pharmaceutical Gets FDA Nod for Liraglutide Raw Materials with DMF Adequacy Letter

Fineline Cube Mar 6, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a China-based pharmaceutical company, has announced that it has...

Company Drug

Shanghai RAAS Receives NMPA Approval to Initiate Clinical Trial for Hemophilia Preventive Treatment

Fineline Cube Mar 6, 2024

Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Three Cancer Treatments Including a Novel ADC

Fineline Cube Mar 6, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, has received separate clinical trial approvals...

Policy / Regulatory

China’s Government Work Report Highlights Biomedicine Innovation and Healthcare Reforms

Fineline Cube Mar 5, 2024

Chinese Premier Li Qiang presented a concise Government Work Report at the Second Session of...

Company Drug

EMA Reviews Datopotamab Deruxtecan Filings from AstraZeneca and Daiichi Sankyo for Oncology Indications

Fineline Cube Mar 5, 2024

The European Medicines Agency (EMA) has accepted for review two oncology filings for the antibody-drug...

Company Drug

Pfizer’s Cibinqo Secures NMPA Approval for Expanded Use in Atopic Dermatitis

Fineline Cube Mar 5, 2024

The National Medical Products Administration (NMPA) has released drug approval certificate delivery information that points...

Policy / Regulatory

China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024

Fineline Cube Mar 5, 2024

The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC), along with three...

Company Drug

Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group

Fineline Cube Mar 5, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that...

Company Deals

Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases

Fineline Cube Mar 5, 2024

California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement...

Company Drug

Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer

Fineline Cube Mar 5, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the...

Company

Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management

Fineline Cube Mar 5, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit...

Company Deals

Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics

Fineline Cube Mar 5, 2024

Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore...

Company Drug

Aosaikang’s Marketing Approval Filing for Delafloxacin Accepted by China’s NMPA

Fineline Cube Mar 5, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...

Company Deals

Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion

Fineline Cube Mar 5, 2024

Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and...

Company Drug

Huadong Medicine’s Arcalyst Filing for Recurrent Pericarditis Accepted by China’s NMPA

Fineline Cube Mar 5, 2024

Huadong Medicine Co., Ltd, (SHE: 000963) a Chinese pharmaceutical company, has announced that the National...

Company Medical Device

Sino Medical Sciences Receives Hong Kong Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Mar 5, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for KRAS G12C Inhibitor Clinical Trial in Advanced Solid Tumors

Fineline Cube Mar 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment

Fineline Cube Mar 5, 2024

HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...

Company Drug

ViiV Healthcare Presents Phase I Data for Ultra-Long-Acting Cabotegravir in HIV Treatment and Prevention

Fineline Cube Mar 5, 2024

GlaxoSmithKline (GSK; NYSE: GSK) unit ViiV Healthcare has presented Phase I results for an ultra-long-acting...

Posts pagination

1 … 439 440 441 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.